Royalty Pharma plc has announced overwhelming shareholder approval for its external manager acquisition, with 99.9% voting in favor at its 2025 Annual General Meeting and Special Meeting of Shareholders. This marks a significant step in the company's transition from an external manager model to an integrated corporate structure. The acquisition is expected to deliver significant financial benefits, including annual cash savings exceeding $100 million in 2026 and growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years. The move aims to strengthen shareholder alignment, enhance corporate governance, and improve economic returns on investments. Royalty Pharma anticipates closing the internalization transaction in May 2025, subject to customary closing conditions and regulatory approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.